Imunon (IMNN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing non-viral DNA technology for immunotherapy and vaccines targeting cancer and infectious diseases.

• Lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, completed Phase II and entering Phase III trials.

• Additional pipeline includes a COVID-19 booster vaccine (IMNN-101) in first-in-human studies.

• Founded in 1982, incorporated in Delaware, and operates as a smaller reporting company.

Financial performance and metrics

• Incurred a net loss of $18.6 million for the year ended December 31, 2024, with cumulative net losses of approximately $407 million.

• Cash and cash equivalents as of December 31, 2024, were $5.9 million.

• Audited financials include a going concern warning due to insufficient cash for at least one year from the audit date.

Use of proceeds and capital allocation

• Estimated net proceeds of $9.0 million if the maximum number of securities are sold, with lower proceeds possible due to the best-efforts structure.

• Proceeds intended for general corporate purposes, clinical development of IMNN-001, capital expenditures, and working capital.

• Management has broad discretion over use of funds, and actual allocation may vary.